Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 25, 2017

DrugPatentWatch Database Preview

RAYALDEE Drug Profile

« Back to Dashboard

What is the patent landscape for Rayaldee, and when can generic versions of Rayaldee launch?

Rayaldee is a drug marketed by Opko Ireland Global and is included in one NDA. There are eight patents protecting this drug.

This drug has fifty-nine patent family members in twenty-three countries.

The generic ingredient in RAYALDEE is calcifediol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the calcifediol profile page.

Summary for Tradename: RAYALDEE

Patents:8
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list44
Patent Applications: see list1,302
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RAYALDEE at DailyMed

Pharmacology for Tradename: RAYALDEE

Ingredient-typeCholecalciferol
Drug ClassVitamin D3 Analog
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Opko Ireland Global
RAYALDEE
calcifediol
CAPSULE, EXTENDED RELEASE;ORAL208010-001Jun 17, 2016RXYesYes8,207,149► Subscribe ► Subscribe
Opko Ireland Global
RAYALDEE
calcifediol
CAPSULE, EXTENDED RELEASE;ORAL208010-001Jun 17, 2016RXYesYes6,582,727► SubscribeY ► Subscribe
Opko Ireland Global
RAYALDEE
calcifediol
CAPSULE, EXTENDED RELEASE;ORAL208010-001Jun 17, 2016RXYesYes9,498,486► Subscribe ► Subscribe
Opko Ireland Global
RAYALDEE
calcifediol
CAPSULE, EXTENDED RELEASE;ORAL208010-001Jun 17, 2016RXYesYes8,906,410► SubscribeY ► Subscribe
Opko Ireland Global
RAYALDEE
calcifediol
CAPSULE, EXTENDED RELEASE;ORAL208010-001Jun 17, 2016RXYesYes8,426,391► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Find generic sources and suppliers
  • Predict branded drug patent expiration
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot